OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Organization: Cognition Therapeutics, Inc.

2 Projects | 1 Researchers | $2,296,968 Invested

2018

Cognition Therapeutics, Inc.

Susan Catalano, PhD

SHINE (Study Synaptic Health and Improvement of Neurological Function with Elayta): A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial

  • Funding Amount: $2,000,000
  • Organization Type: Biotechnology/For Profit
  • Program: Clinical
  • Target: Neuronal Degeneration
  • Status: Closed

2010

Cognition Therapeutics, Inc.

Susan Catalano, PhD

Behavioral efficacy testing of anti-Abeta 42 oligomer small molecules

  • Funding Amount: $296,968
  • Organization Type: Biotechnology/For Profit
  • Program: Drug Discovery
  • Status: Closed